News
BLUE
0.9125
-1.13%
-0.0104
Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapies
Walgreens Boots Alliance expands specialty pharmacy with unit dedicated to cell and gene therapies. Walgreens expects to be largest provider of specialty pharmacy services with $24B in annual revenue. The company's focus on gene and cell therapies comes months after first gene-editing therapy was approved.
Seeking Alpha · 17h ago
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys. Global stock indices continued an upward trend in March, with both U.S. Stocks rising by 3%. Nvidia unveiled its groundbreaking Blackwell chip at GTC 2024. The S&P 500 recorded its longest positive monthly streak since 2021.
Seeking Alpha · 19h ago
Crispr Therapeutics: Now Is The Time To Buy
CRISPR Therapeutics' stock has declined in value despite recent FDA approvals for its groundbreaking gene editing technology. The company's pipeline of treatments for various diseases presents a significant opportunity for future growth and market expansion. CRISPR has enough cash on hand to fund operations for at least 24 months.
Seeking Alpha · 1d ago
Hercules Capital: Winning Option In The Financial Services Space
Seeking Alpha · 1d ago
Weekly Report: what happened at BLUE last week (0415-0419)?
Weekly Report · 3d ago
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
TipRanks · 6d ago
BUZZ-bluebird delays filing of Q1 and 2023 reports, shares fall
Bluebird bio's shares fall 3% to 96 cents in extended trading. Gene therapy developer delays filing of Q1 and 2023 reports. Company says delays due to work required to restate financial statements. Company's stock down 70.8% in the past 12 months.
Reuters · 04/16 21:38
Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024
Benzinga · 04/16 20:26
BLUEBIRD BIO INC - ANTICIPATES IT WILL BE DELAYED IN FILING ITS QUARTERLY REPORT ON FORM 10-Q FOR THE FIRST QUARTER OF 2024
Reuters · 04/16 20:08
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
NASDAQ · 04/16 18:05
TD Cowen says sickle cell therapies may get higher CMS payments
Healthcare TD Cowen says sickle cell therapies may get higher CMS payments. Vertex/CRISPR’s Casgevy and bluebird bio's Lyfgenia were approved by the FDA for sicklecell disease in December. The two new therapies for the disease may get enhanced payments under proposed guidelines by CMS.
Seeking Alpha · 04/15 20:46
Is Bluebird Bio Stock a Buy?
Bluebird Bio has three products on the market, but the company isn't profitable. Bluebird Bio's gene therapies are complex and expensive to manufacture and administer to patients. The company only has two programs, both of which are gene therapies for sickle cell disease. The small biotech's financial constraints may prevent it from truly taking off.
The Motley Fool · 04/15 12:15
Weekly Report: what happened at BLUE last week (0408-0412)?
Weekly Report · 04/15 09:11
Better Buy: Bluebird Bio Vs. Novavax
Bluebird Bio and Novavax are two beaten-down biotechs. Bluebird's stock is down 91% in the past three years, while NovavAX's has declined 97%. Both companies are developing innovative gene editing therapies. But Bluebird Bio is the better option for aggressive, contrarian investors.
The Motley Fool · 04/13 20:22
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against BlueBird Bio, Inc. (NASDAQ: BLUE)
A class action lawsuit was filed in the U.S. District Court for the District of Massachusetts against BlueBird Bio, Inc. On March 28, 2024. The complaint alleges violations of federal securities laws. Plaintiff seeks to recover damages on behalf of all shareholders. You may move the Court no later than May 28, 2025 to be a lead plaintiff.
Barchart · 04/12 16:24
BLUE Shareholders with Significant Losses are Urged to Contact Robbins LLP to Discuss the bluebird bio, Inc. Class Action
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased bluebird bio, Inc. Common stock. Bluebird is a biotechnology company that develops gene therapies for severe genetic diseases. Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc., Overstated the Clinical and/or Commercial Prospects of its Drug.
Barchart · 04/12 16:12
Is This Beaten-Down Stock a Good Acquisition Target?
Bluebird Bio's share price has slumped 60% in the past 12 months. The small-cap gene-editing specialist is a potential acquisition target for a larger company. Bluebird Bio is an innovative company with three approved therapies for rare diseases. The biotech could benefit from the financial support of a larger drugmaker. But the company's shares look too risky to invest in now.
The Motley Fool · 04/11 12:30
BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Investors have until May 28, 2024 to seek appointment as lead plaintiff of the bluebird bio class action lawsuit. Robbins Geller Rudman & Dowd LLP is one of the world’s leading securities class action firms. The company is a biotechnology company that develops gene therapies for severe genetic diseases. If you suffered substantial losses and wish to serve as a lead plaintiff, please contact the firm.
Barchart · 04/09 06:55
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Bluebird Bio, Sarepta Therapeutics and Jazz Pharmaceuticals have received a lot of coverage today. Bluebird Bio has a Hold rating from RBC Capital, while Sarepta Therapeutic has a Buy rating from Citi. The Healthcare sector has been the subject of a number of analyst reports.
TipRanks · 04/09 02:00
Weekly Report: what happened at BLUE last week (0401-0405)?
Weekly Report · 04/08 09:12
More
Webull provides a variety of real-time BLUE stock news. You can receive the latest news about Bluebird Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About BLUE
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).